Critical Review: Bicara Therapeutics (BCAX) versus Its Competitors

Bicara Therapeutics (NASDAQ:BCAX) is one of 620 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Bicara Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Insider and Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.6% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bicara Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bicara Therapeutics	N/A	-$68.00 million	-3.57
Bicara Therapeutics Competitors	$917.71 million	-$44.28 million	-0.56

Bicara Therapeutics’ competitors have higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Bicara Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-21.67%	-20.89%
Bicara Therapeutics Competitors	-1,418.64%	-631.15%	-29.14%

Analyst Recommendations

This is a breakdown of recent recommendations for Bicara Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	1	8	1	3.00
Bicara Therapeutics Competitors	3624	11405	35997	1001	2.66

Bicara Therapeutics presently has a consensus price target of $32.2513, suggesting a potential upside of 184.91%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 2,470.05%. Given Bicara Therapeutics’ competitors higher probable upside, analysts clearly believe Bicara Therapeutics has less favorable growth aspects than its competitors.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.